Clinical data | |
---|---|
Trade names | Diprivan, others[1] |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Dependence liability | Physical: Very High Psychological: no data |
Addiction liability | Moderate[2] |
Routes of administration | Intravenous |
Drug class | GABA receptor agonist; sedative; hypnotic |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | NA |
Protein binding | 95–99% |
Metabolism | Liver glucuronidation |
Onset of action | 15–30 seconds[5] |
Elimination half-life | 1.5–31 hours[5] |
Duration of action | ~5–10 minutes[5] |
Excretion | Liver |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.016.551 |
Chemical and physical data | |
Formula | C12H18O |
Molar mass | 178.275 g·mol−1 |
3D model (JSmol) | |
Solubility in water | ΔGsolvH2O = -4.39kcal/mol[6] |
| |
| |
(verify) |
Propofol[7] is the active component of an intravenous anesthetic formulation used for induction and maintenance of general anesthesia. It is chemically termed 2,6-diisopropylphenol. The formulation was approved under the brand name Diprivan. Numerous generic versions have since been released. Intravenous administration is used to induce unconsciousness after which anesthesia may be maintained using a combination of medications. It is manufactured as part of a sterile injectable emulsion formulation using soybean oil and lecithin, giving it a white milky coloration.[8]
Recovery from propofol-induced anesthesia is generally rapid and associated with less frequent side effects[9][10] (e.g. drowsiness, nausea, vomiting) compared to other anesthetic agents. Propofol may be used prior to diagnostic procedures requiring anesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anesthesia prior to and during surgeries. It may be administered as a bolus or an infusion, or some combination of the two.
First synthesized in 1973, by John B. Glen, a British veterinary anesthesiologist working for Imperial Chemical Industries (ICI, later AstraZeneca),[11] in 1986 propofol was introduced for therapeutic use as a lipid emulsion in the United Kingdom and New Zealand. Propofol (Diprivan) received FDA approval in October 1989. It is on the World Health Organization's List of Essential Medicines.[12]
Propofol is a general anesthetic, however its abuse for recreational purpose has been documented (120). Using control drugs implicated in both ΔFosB induction and addiction (ethanol and nicotine), similar ΔFosB expression was apparent when propofol was given to rats. Moreover, this cascade was shown to act via the dopamine D1 receptor in the NAc, suggesting that propofol has abuse potential (119)